Percutaneous Microwave Ablation under Ultrasound Guidance for Renal Cell Carcinomas at Clinical Staging T1: A Comparative Study of Clinical Results for Patients Aged Between Less Than 65 Years and 65 Years and Older.
Zhigang Cheng,Xiao-ling Yu,Zhiyu Han,Fang-yi Liu,Jie Yu,Ping Liang
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e16574
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:e16574 Background: Renal cell carcinoma (RCC) is the second most common malignant tumor of the urinary system in China. With the extension of the life expectancy of the population, the incidence of kidney cancers have shown gradually increasing trends and been commonly detected in patients aged 65 years and older with the mortality rate of 67.7%, most of whom suffered poor renal functional preservation or multiple comorbidities. Compared to partial nephrectomy (PN), microwave ablation (MWA) has been considered as one of the best indications for selected clinical T1 (cT1) RCC in elder patients. The purpose of the study was to evaluate the clinical results of patients aged 65 years and older with cT1 RCCs treated by percutaneous microwave ablation under ultrasound (US) guidance, compared to those less than 65. Methods: From September 2009 to December 2016, clinical data of MWA treatment for RCCs in two groups with the similar mean diameters in baseline, Group O (65 years and older) including 75 patients with 76 RCCs and Group Y (less than 65 years) including 91 ones with 99 RCCs, were retrospectively assessed. The technical efficacy, cumulative overall survival (OS) and disease-free survival (DFS), local tumor progression (LTP), major and minor complications, and renal function including serum creatinine (Cr) and blood urea nitrogen (BUN) between the two groups were statistically evaluated by SPSS. Results: After ablation, there were no statistical significances between the two groups at technical efficacy, LTP, major and minor complications. The cumulative OS and DFS rates at 1, 3, 5 years in Group O vs. Group Y were 100%, 92.6%, 92.6% vs. 100%, 96.9%, 90.9% (p = 0.701) and 100%, 92.5%, 92.5% vs. 98.6%, 98.6%, 90.4% (p = 0.697), respectively. There were no significant differences both serum Cr and BUN between the two groups before MWA and at the last follow-up. Conclusions: Compared to those less than 65 years, US-guided percutaneous MWA for cT1 RCCs could achieve coincident clinical results in patients 65 years and older, and then can be recommended one of optimal alternative treatment for selected older patients.